Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò, +15

The Lancet Oncology

Surgical OncologyMalignant DiseaseRelapsed Malignant MesotheliomaMedicinePlacebo-controlled Phase 2B +6

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak, +23

The Lancet Respiratory Medicine

Placebo-controlled Phase 3Pleural DiseaseAnti-cancer AgentCancer TreatmentOncology +4

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Federica Grosso, Nicola Steele, Silvia Novello, +15

Journal of Clinical Oncology

Cancer ManagementPathologyMetronomic ChemotherapyGliomaOncology +14

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study

Dean A. Fennell, Paul Baas, Paul Taylor, +12

Journal of Clinical Oncology

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec, +16

The Lancet Oncology

Ezh2 Inhibitor TazemetostatMalignant DiseaseMedicineImmunologyPathology +5

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

Eric Lim, David Waller, Kelvin Lau, +50

The Lancet Respiratory Medicine

Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

Eric Lim, Liz Darlison, John Edwards, +31

BMJ Open

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

Vanesa Gregorc, Rabab Gaafar, Adolfo Favaretto, +15

The Lancet Oncology

Malignant Pleural MesotheliomaPlacebo-controlled Phase 3MedicinePleural DiseaseBest Investigator Choice +5

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Hedy L. Kindler, Silvia Novello, Alessandra Bearz, +24

The Lancet Oncology

Open-label Phase 2Pleural DiseaseOncologyRadiation OncologyRadiology +1

Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program

Paul Taylor, B. Castagneto, G. Dark, +12

Journal of Thoracic Oncology

Surgical OncologyOncologyMalignant Pleural MesotheliomaPleural DiseaseSingle-agent Pemetrexed +2